BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, November 18, 2025
See today's BioWorld
Home » US FDA approvals up 20% year-over-year, average 14 a month in 2023
To read the full story, subscribe or sign in.
Biopharma regulatory actions and approvals July 2023

US FDA approvals up 20% year-over-year, average 14 a month in 2023

Aug. 18, 2023
By Amanda Lanier
Drug approvals by the U.S. FDA increased 20.48% compared to the first seven months of 2022, even with July approvals slightly down to 13 from the previous six months’ average of 14.5 per month. Worldwide approvals from January to July are down 13.8% from the same period last year.
BioWorld Analysis and data insight Regulatory

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Nov. 17, 2025.
  • Art concept for medical research

    With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

    BioWorld
    Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...
  • Art concept for medical research

    With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

    BioWorld Science
    Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...
  • Illustration of magnifying glass inspecting brain

    Anchoring, and bootstrapping, psychiatry into the precision medicine era

    BioWorld
    Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing